Easy to Use Trio Mobile Computing Workstation Introduced by Capsa Healthcare

Trio mobile computing workstation is the latest generation point-of-care platform from Capsa Healthcare to mobilize e-health records and support efficient and accurate medication management.

Trio mobile computing workstation incorporates the latest technology in a blended design of the most intelligent and most reliable computing carts ever offered. Trio provides a refined ergonomic style coupled with advances in ease of use, maneuverability, and power system runtime. Along with traditional needs for clinical documentation and medication administration, Trio can be configured to support a variety of applications including telehealth, registration, and phlebotomy.

“Capsa is pleased to deliver a solution that combines the reliability of our proven platforms with enhanced intelligent features that customers expect in today’s mobile computing workstations,” says Avi Zisman, Capsa’s President and CEO. “With the addition of Trio, our product portfolio now offers customers an unmatched scope of solutions that support healthcare delivery at the point-of-care.”

Trio mobile computing workstation is Capsa Healthcare’s most advanced workstation with enhancements that support a clinician’s essential role:

  • Intuitive control center with touch screen navigation to helpful information, communication tools, and memory presets for each user
  • N-Stride steer assist and a lightweight, small footprint for ease-of-mobility
  • New scalable GoLife™ power platform for extended runtime, exceeding 24 hours
  • New MaxBin flexible storage system for any medication administration workflow, with high-capacity bins and soft-close drawers
  • Enhanced N-Sight™ cloud-based fleet management software to assist I.T. in managing cart assets in a facility or across a health system
  • Easy-to-clean smooth surfaces and an embedded antimicrobial additive on high touch points

“Providing clinicians with an intuitive and optimized user experience to support their patient care routine is at the heart of the Trio design. With a focus on user specific ergonomics and superior performance, wrapped into a lightweight, small form factor workstation, we have developed a solution that will serve as a caregiver’s most reliable partner at the point-of-care”, says Craig Rydingsward, VP of Sales, Acute Care at Capsa Healthcare. “Trio’s innovative advances in power system runtime combined with robust fleet management and communication capabilities now offered in N-Sight, enable I.T. and administration to realize true value in their POC fleet.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version